{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=10", "query": { "intervention": "Continuous Dose", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 5319, "total_pages": 532, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T13:21:32.474Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01142986", "title": "Evaluating Three Methods for Helping Syringe Exchangers Begin Methadone Maintenance", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Substance Abuse Disorder" ], "interventions": [ { "name": "Low intensity care", "type": "BEHAVIORAL" }, { "name": "Voucher reinforcement", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 223, "start_date": "2010-07", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2018-07-30", "last_synced_at": "2026-10-31T13:21:32.474Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01142986" }, { "nct_id": "NCT00069095", "title": "A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Oxaliplatin 130 mg/m^2", "type": "DRUG" }, { "name": "Capecitabine 1000 mg/m^2", "type": "DRUG" }, { "name": "Bevacizumab 7.5 mg/kg", "type": "DRUG" }, { "name": "Placebo for bevacizumab 7.5 mg/kg", "type": "DRUG" }, { "name": "Oxaliplatin 85 mg/m^2", "type": "DRUG" }, { "name": "Leucovorin 200 mg/m^2", "type": "DRUG" }, { "name": "Fluorouracil 400 mg/m^2", "type": "DRUG" }, { "name": "Bevacizumab 5 mg/kg", "type": "DRUG" }, { "name": "Placebo for bevacizumab 5 mg/kg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2035, "start_date": "2003-07", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2016-10-06", "last_synced_at": "2026-10-31T13:21:32.474Z", "location_count": 49, "location_summary": "Berkeley, California • Fountain Valley, California • Fullerton, California + 44 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Gilroy", "state": "California" }, { "city": "Greenbrae", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00069095" }, { "nct_id": "NCT00818441", "title": "Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-small Cell" ], "interventions": [ { "name": "Dacomitinib (PF-00299804)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 119, "start_date": "2009-03-11", "completion_date": "2015-04-30", "has_results": true, "last_update_posted_date": "2019-01-08", "last_synced_at": "2026-10-31T13:21:32.474Z", "location_count": 31, "location_summary": "Orange, California • Pleasant Hill, California • Salinas, California + 15 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Pleasant Hill", "state": "California" }, { "city": "Salinas", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00818441" }, { "nct_id": "NCT00110305", "title": "A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Immunodeficiency Virus Type 1" ], "interventions": [ { "name": "TMC278 25 mg", "type": "DRUG" }, { "name": "TMC278 75 mg", "type": "DRUG" }, { "name": "TMC278 150 mg", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" }, { "name": "Non-nucleoside reverse transcriptase inhibitor (NRTIs)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tibotec Pharmaceuticals, Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 368, "start_date": "2005-06", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2014-06-25", "last_synced_at": "2026-10-31T13:21:32.474Z", "location_count": 9, "location_summary": "Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 6 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00110305" }, { "nct_id": "NCT02198794", "title": "Reducing Involuntary Movements in Participants With Tardive Dyskinesia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Tardive Dyskinesia" ], "interventions": [ { "name": "SD-809", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Auspex Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 343, "start_date": "2014-10-20", "completion_date": "2020-12-14", "has_results": true, "last_update_posted_date": "2022-04-01", "last_synced_at": "2026-10-31T13:21:32.474Z", "location_count": 44, "location_summary": "Tuscaloosa, Alabama • Anaheim, California • Glendale, California + 36 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Anaheim", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02198794" }, { "nct_id": "NCT03291951", "title": "FOcus on Reducing Dose-limiting Toxicities in Colon Cancer With Resistance Exercise Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Resistance Training", "Colon Cancer", "Chemotherapy Effect" ], "interventions": [ { "name": "Resistance training", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Kaiser Permanente", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 183, "start_date": "2018-02-23", "completion_date": "2022-03-21", "has_results": false, "last_update_posted_date": "2022-07-28", "last_synced_at": "2026-10-31T13:21:32.474Z", "location_count": 3, "location_summary": "Oakland, California • Boston, Massachusetts • Hershey, Pennsylvania", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03291951" }, { "nct_id": "NCT06751056", "title": "Cervical Traction to Reduce Gabaergic Medication Use for Neuropathic Itch", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pruritus" ], "interventions": [ { "name": "Cervical Traction Device", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2025-06-01", "completion_date": "2027-01-10", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-31T13:21:32.474Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06751056" }, { "nct_id": "NCT06078696", "title": "Siplizumab for Sickle Cell Disease Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Anemia, Sickle Cell" ], "interventions": [ { "name": "Siplizumab", "type": "DRUG" }, { "name": "Exchange Transfusion", "type": "PROCEDURE" }, { "name": "Total Body Irradiation", "type": "PROCEDURE" }, { "name": "Stem Cell Infusion", "type": "PROCEDURE" }, { "name": "Cyclophosphamide 50mg", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Sirolimus Oral Tablet", "type": "DRUG" }, { "name": "Rituximab or Biosimilar", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 1, "start_date": "2023-09-28", "completion_date": "2025-12-11", "has_results": true, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-10-31T13:21:32.474Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06078696" }, { "nct_id": "NCT07276542", "title": "Clinical Trial Exploring the Outpatient Treatment of Phantom Limb Pain With Ketamine Administration in a Six Month Study With a Minimum Remission Period of 7 Days Between Treatment Session. 25-30 Subjects With an Ongoing History of Significant PLP.--FDA and IRB Approved.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Phantom Limb Syndrome With Pain" ], "interventions": [ { "name": "IM ketamine in dose finding and then continuation", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Ketamine Research Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2026-01-15", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-10-31T13:21:32.474Z", "location_count": 4, "location_summary": "Sacramento, California • San Anselmo, California • Santa Monica, California + 1 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "San Anselmo", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT07276542" }, { "nct_id": "NCT05455294", "title": "Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myeloid Malignancy", "Myelodysplastic Syndromes", "Myelofibrosis", "Acute Myeloid Leukemia", "Myeloproliferative Neoplasm" ], "interventions": [ { "name": "Navitoclax", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jacqueline Garcia, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2022-07-18", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-01-28", "last_synced_at": "2026-10-31T13:21:32.474Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05455294" } ] }